-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 2, 2024 | 
nature.com | Joseph McGuirk |Leland Metheny III |Mark Litzow |Scott Rowley |Roni Tamari |Hillard M. Lazarus
Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02068-3, published online 08 August 2023Following the publication of this article, the authors would like to add an additional reference as below to add context on the original discovery of PLX-R18's proposed therapeutic capabilities:16. Gaberman E, Pinzur L, Levdansky L, Tsirlin M, Nete~ N, Aberman Z, et al.
-
Sep 6, 2024 | 
digitalcommons.library.tmc.edu | Christopher J. Ferreri |Hamza Hashmi |Leyla O. Shune |Joseph McGuirk
AbstractMost patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers.
-
May 30, 2024 | 
nature.com | Danai Dima |James Davis |Hussein Awada |Faiz Anwer |Shahzad Raza |Zahra Mahmoudjafari | +2 more
AbstractThe presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) chimeric antigen receptor (CAR) T-cell therapy and had active extraosseous EMD before the infusion. Data were retrospectively collected from patients at three US institutions with the intent to receive SOC CAR T.
-
Apr 11, 2024 | 
nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more
Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].
-
Dec 12, 2023 | 
newsbreak.com | Joseph McGuirk
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
-
Dec 12, 2023 | 
onclive.com | Joseph McGuirk
Video synopsis is AI-generated and reviewed by OncLive editorial staff. The field of cancer immunotherapy is witnessing significant innovations, particularly in the treatment of non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL). One major challenge is the time it takes to manufacture CAR T-cell therapies, which can range from a month to a month and a half.
-
Dec 5, 2023 | 
newsbreak.com | Joseph McGuirk
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
-
Dec 5, 2023 | 
onclive.com | Joseph McGuirk
Video synopsis is AI-generated and reviewed by OncLive editorial staff. CAR T-cell therapy, a promising treatment for lymphoma patients, faces significant challenges in terms of access and treatment responses. A key issue is the eligibility gap; while approximately 25,000 patients in the United States receive a diagnosis of diffuse large B-cell lymphoma (DBCL) annually, a substantial disparity exists between the number of eligible patients and those who actually receive CAR T-cell therapy.
